50P - Droplet digital PCR measurement of c-Met gene amplification in plasma cell free DNA in patients with advanced NSCLC

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Hong-Fei Gao
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors H. Gao, X. Zhang, J. Yang, Y. Wu
  • Lung Cancer, Guangdong General Hospital, 510080 - Guangzhou/CN



Advanced NSCLC patients with c-Met amplification can respond to c-Met inhibitors. Unfortunately, the lack of adequate tissue often precludes c-Met testing. We hypothesized that plasma cell-free DNA (cfDNA) can offer an alternative source of biologic material for testing.


We designed a target region on exon 4 of c-Met gene, used RNaseP as the reference gene. We evaluated this c-Met:RNaseP ddPCR assay to determinate c-Met amplification in plasma cfDNA in 34 patients with advanced NSCLC who received c-Met inhibitor therapy, results were correlated with clinical findings.


The concordance rate of ddPCR with FISH was not high (55.9%); however, patients who were c-Met-positive by ddPCR had significantly longer PFS after c-Met inhibitor therapy compared with c-Met-negative patients (4.352 months and 1.657 months, respectively, P = 0.008).


Our results demonstrated that this ddPCR method can be used to evaluate c-Met status in plasma cfDNA samples. The c-Met status determined in cfDNA may have potential as a predictive factor for PFS after c-Met inhibitor therapy.

Clinical trial indentification

not a clinical trial

Legal entity responsible for the study





All authors have declared no conflicts of interest.